



Lund June 24, 2014

Bone Scan Index (BSI) as therapy-monitoring imaging biomarker, to be presented at the 2014 German Congress for Urology, DGU, in Düsseldorf.

The Martini Clinic, renowned German Prostate Cancer Centre at the University of Hamburg, UKE, will present a study based on PCa-patients undergoing advanced treatment with the drug substance Abiraterone, at this year's annual German Congress for Urology (DGU) in Düsseldorf.

The study was performed by the Martini clinic, Autumn 2013 through spring 2014, on patients treated for metastasized prostate cancer. The patients were monitored using the software EXINI bone^{BSI}, which automatically calculate and provide BSI-value to attending physicians and staff.

Results from the study will be orally presented at the DGU-congress, demonstrating BSI as a reliable biomarker in monitoring disease progress and treatment response.

The DGU-presentation title:

Automated quantification of the metastatic burden of castration resistant prostate cancer patients: Observer independent monitoring of disease progression. (*Automatisierte Quantifizierung der Metastasenlast bei kastrations-resistenten Prostatakarzinompatienten: Untersucher-unabhängiges Monitoring des Krankheitsverlaufes*)

"An oral presentation at the prestigious DGU-congress is a success and an acknowledgment to our work on the German market", remarks Fredrik Luttrupp, Sales Manager Germany, EXINI Diagnostics AB

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkommission AB acts as Certified Advise